↓ Skip to main content

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Overview of attention for article published in Breast Cancer Research, January 2021
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
55 Mendeley